-Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. -ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed. HONG KONG, Jan. 26, 2026 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants have been dosed in a U.S. 13-week Phase II study (NCT07321678) with ASC30, an oral small molecule GLP-1 r
TIANJIN, China, Jan. 26, 2026 -- In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency's Master File acknowledgement letter, issued on January 9, 2026, incorporates the "Tasly 3P Characterization of MSCs Assay" (MF 32345) into its regulatory framework. This step provides long-sought guidance to ensure the consistent, safe, and effective clinical use of MSCs. Historically misclassifie
[ 메디채널 김갑성 기자 ] 톈진, 중국 2026년 1월 26일 -- 미국 식품의약국(FDA)이 중간엽 기질세포(Mesenchymal Stromal Cells, MSC)를 위한 최초의 전용 품질관리 기준을 담은 디바이스 마스터 파일(Device Master File, DMF)을 승인했다. 세포치료 산업 전반에 중대한 전환점이 될 이번 조치로 MSC의 일관되고 안전하며 효과적인 임상 활용을 보장하기 위해 오랫동안 요구되어 온 규제 지침이 처음으로 마련됐다. FDA는 2026년 1월 9일 발행한 마스터 파일 승인 확인서를 통해 '타슬리 3P 중간엽 기질세포 특성 분석 시험(Tasly 3P Characterization of MSCs Assay)'(MF 32345)을 공식 규제 체계에 포함했다. 그동안 MSC는 줄기세포로 잘못 분류됐으며, 명확한 품질 기준의 부재로 인해 임상 결과의 편차가 발생했다. 새롭게 인정된 '3P' 분석법은 속성(Property, 세포 정체성), 순도(Purity, 오염 여부), 효능(Potency, 기능적 활성)이라는 세 가지 핵심 요소를 평가함으로써 이러한 문제를 직접 해결한다. 이를 통해 치료용 MSC
[ 메디채널 김갑성 기자 ] Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. ISM8969 is a novel oral therapeutic candidate developed through Insilico's Pharma.AI, with best-in-class potential, unique brain penetrant traits, and favorable druggability profiles demonstrated in preclinical studies. Insilico Medicine has entered into a co-development collaboration agreement with Hygtia Therapeutics, with bo
[ 메디채널 황정호 기자 ] ラスベガス、2026年1月23日 -- すべてのハンターやアウトドアのプロフェッショナルにとって、視認性は重要です。特に、低照度、完全な暗闇、長距離、複雑な地形といった厳しい条件の場合、従来の光学機器では限界があり、ターゲットの認識や識別が難しくなることが少なくありません。Guide Outdoorは、実世界のシナリオでハンターをより的確に支援するため、ApexVision搭載のTU1260MSマルチスペクトルスコープを発表します。これは、昼夜を問わず、超クリアで正確なイメージングを提供する新たな基準となります。 TU1260MSは、広範なフィールドテストとハンターからのフィードバックに基づき、細部まで改良され、すでに高性能な狩猟用光学機器として認知されています。最新のサーマルイメージング技術を採用したApexVisionにより、画像の忠実度が向上し、動きはより滑らかになり、細部にいたるまでシャープに描写されます。一刻を争う場面で、ハンターにより強い自信をもたらします。 ApexVisionが実世界での狩猟性能を向上させる仕組み TU1260MSは、1280×1024のサーマルセンサーと1920×1080の低照度CMOSセンサーによる強力なデュアルセンサーを搭載し、NETD≤15
[ 메디채널 황정호 기자 ] 라스베이거스, 2026년 1월 23일 -- 사냥꾼과 아웃도어 전문가에게 선명도는 중요한 요소다. 특히 저조도, 칠흑 같은 어둠, 원거리, 복잡한 지형 등 까다로운 조건에서는 기존 광학 장비가 표적 인식 및 식별에서 한계를 드러낸다. 이러한 실전 상황에 대응하기 위해 가이드 아웃도어(Guide Outdoor)는 ApexVision 기술을 적용한 TU1260MS 멀티스펙트럴 스코프(TU1260MS Multi-Spectral Scope)를 선보이며, 주•야간 사냥을 위한 초고선명•고정밀 이미징의 새로운 기준을 제시했다. 광범위한 현장 테스트와 전문 사냥꾼들의 피드백을 바탕으로 완성된 TU1260MS는 이미 고성능 사냥용 광학 장비로 인정받고 있다. 여기에 최신 열화상 혁신 기술인 ApexVision이 더해져, 이미지 충실도가 향상되고 움직임은 더욱 부드러워졌으며 디테일은 레이저처럼 선명해졌다. 이를 통해 매 순간이 중요한 사냥 현장에서 사냥꾼들에게 더 큰 자신감을 부여한다. ApexVision으로 강화된 실전 사냥 성능 TU1260MS는 1280×1024 해상도의 강력한 열화상 센서
Adesanya joins Tradeify as Global Brand Ambassador Announcement comes ahead of the UFC icon's return to the octagon against Joe Pyfer at UFC Seattle on March 28 Partnership marks the second chapter of Tradeify's Champion Mindset campaign MIAMI, Jan. 23, 2026 -- Tradeify, the global trader evaluation platform, today announces a long-term partnership with UFC legend and two-time middleweight champion Israel Adesanya, who joins the brand as its new Global Brand Ambassador. The Champion Mindset, Chapter II: Adaptability with Israel Adesanya The partners
라이프
Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard
엔터
The Billion Dollar Brushstroke: Attorney's art platform secures $1B+ in committed listings in first month - positioned for rapid growth.
라이프
미 FDA, 중간엽 기질세포(MSC) 첫 품질관리 기준 승인…세포치료 새 기준 제시
MIAMI and TAIPEI, Jan. 21, 2026 -- Shaklee, a global leader in health and wellness, today announced the appointment of Scarlett Su as President of Shaklee Taiwan, effective immediately. Scarlet brings extensive leadership experience in the direct selling and wellness industries, with a strong track record of driving sustainable growth through high-performance team culture, innovative social media strategies, and community-focused marketing initiatives. She has spent over 30 years helping build and scale successful local brands, including more than a decade in senior leadership
HONG KONG, Jan. 20, 2026 -- Beauty Farm Medical and Health Industry Inc. ("Beauty Farm" or the "Company") (02373.HK), one of the largest beauty and wellness services providers in China, issued a positive profit alert for the year ended December 31, 2025. As disclosed, the Company anticipates revenue of not less than RMB 3.0 billion for the year ended December 31, 2025, representing robust growth of not less than 16% compared with the corresponding period in 2024. Based on a preliminary assessment of the unaudited results, Beauty Farm expects an adjusted net profit o
[ 메디채널 노기식 기자 ] Battle of the Purple Champions marks a milestone celebration of movement, community, and the kampong spirit as the brand reaches 150 clubs islandwide SINGAPORE, Jan. 7, 2026 -- This 31st January 2026, OCBC Square will turn purple as Anytime Fitness, the world's largest 24-hour fitness brand, rallies Singapore to move together at its first-ever fitness festival: [ 메디채널 노기식 기자 ] Battle of the Purple Champions (BOPC), powered by Skechers. More than just a competition, BOPC is a celebration of the people and community that have powered Anytime Fitness' gr